Justin Kelley, DO
Orthopaedic Surgery · Sandusky, OHNPI 1205256187
Payments from drug & device makers
Across 75 payments — averaging $156.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Zimmer Biomet$6K
- Si-bone, Inc.$4K
- Globus Medical$1K
- Biotissue Holdings Inc.$402
- Smith+Nephew$145
- Integra Lifesciences Corporation$129
- plus $536 from 11 others
What the payments were for
- Consulting fees$2,50021%
- Travel & lodging$5,48647%
- Food & beverage$3,60031%
- Education$1341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Zimmer Biomet | 29 | $5,595 |
| Si-bone, Inc. | 14 | $3,902 |
| Globus Medical | 5 | $1,011 |
| Biotissue Holdings Inc. | 2 | $402 |
| Smith+Nephew | 1 | $145 |
| Integra Lifesciences Corporation | 1 | $129 |
| Rock Medical Orthopedics, Inc. | 5 | $116 |
| Organogenesis Inc. | 4 | $100 |
| Hydrocision, Inc. | 1 | $77 |
| Pacira Pharmaceuticals Incorporated | 3 | $67 |
| Endo USA, Inc. | 2 | $37 |
| Endo Pharmaceuticals Inc. | 3 | $37 |
| Stryker | 1 | $28 |
| Davol Inc. | 1 | $25 |
| Vericel Corporation | 1 | $17 |
| Vertex | 1 | $17 |
| Bioventus LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IFUSE IMPLANT SYSTEM$3,029
- ROSA$1,492
- Persona$1,413
- Clavical Fixation (16-186)$958
- mymobility Platform$373
- Oxford$353
- iFuse Implant$191
- TAPESTRY$147
- EVOS$145
- TRIGEN InterTAN$145
- TENOGLIDE$129
How this compares
$11,721 in reported general payments places this provider in the 70th percentile of 794 orthopaedic surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $5,952 |
| Celecoxib | 42 | $1,435 |
| Meloxicam | 154 | $541 |
| Oxycodone Hcl | 89 | $538 |
| Tramadol Hcl | 167 | $529 |
| Methylprednisolone | 73 | $401 |
| Doxycycline Hyclate | 51 | $357 |
| Diclofenac Sodium | 13 | $194 |
| Naproxen | 30 | $189 |
| Cyclobenzaprine Hcl | 55 | $183 |
| Ibuprofen | 14 | $73 |
| Amoxicillin | 45 | $22 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Sandusky
- Reuben GobezieCleveland$12.6M
- Brad PichaIndependence$12.3M
- Gregory BerletWorthington$9.9M
- Wael BarsoumCleveland$8.9M
- Brian CohenChillicothe$8.9M
- Joseph IannottiCleveland$7.1M
- John SontichYoungstown$3.6M
- Anthony MiniaciCleveland$3.1M
- Mark FroimsonCleveland$2.9M
- David WelkerMiamisburg$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.